Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal aaMSCs for ALS
NCT03268603Phase 2Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Oct 2017
- Primary completion
- Jan 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous adipose-derived mesenchymal stromal cells in amyotrophic lateral sclerosis (ALS), sponsored by Mayo Clinic. Primary endpoint: Adverse Events at 12 months. Started Oct 2017; status: active, not recruiting.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03268603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03268603.